Featured Story BioCentury & Getty ImagesCongress won’t adopt Pelosi’s price controls, but it may revamp Medicare Part D

The fate of drug pricing legislation, and the fortunes of American patients and biopharmaceutical companies, hinge on calculations five politicians will make over the coming 100 days. If leadership in ...

Featured Story BioCentury & Getty ImagesFDA’s international drug review pilot could simplify cancer trials, get drugs to patients faster

FDA believes its new framework for the submission and review of cancer drugs concurrently in multiple countries will speed up patient access to new therapies and streamline drug development. The ...

Featured Story Laures / iStock / Getty ImagesIndustry seeks ICH revisions to curb influx of irrelevant pharmacovigilance data

The mounds of post-market safety data now being generated through social media and other non-traditional data sources are overwhelming regulators and often hindering pharmacovigilance, not improving ...

Featured Story BioCentury & Getty ImagesCFIUS’s genetic data criteria could ensnare more biotech investments

Regulations proposed by the Trump administration would require scrutiny and government approval of foreign investment in a broad swath of private biotechs, including all companies that conduct ...

Emerging Company Profile BioCentury & Getty ImagesBoundless Bio: designing cancer therapies around extrachromosomal DNA

With a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio is opening up a new target space in cancer by combining a commercially explored concept in tumor ...

Politics, Policy & Law BioCentury & Getty ImagesForeign investment in U.S. biotech will become harder, and stay harder

It would be easy to brush aside the government’s increased scrutiny of foreign investments in U.S. companies in the interest of national security as either a temporary symptom of the trade war or a ...

Finance ULTRAMARINFOTO/ISTOCK/GETTY IMAGELetter to the Editor: Business Roundtable vs. the social contract

In a Sept. 13 Editor’s Comment in BioCentury, our Washington Editor Steve Usdin writes about the importance of the biopharmaceutical industry renewing its commitments to the social contract under ...

Finance BioCentury & Getty ImagesThemis preps first clinical test of oncolytic viral approach with €40M round

As Themis continues to develop vaccines using its measles viral vectors to treat infectious diseases, the Austrian biotech also hopes to use its new €40 million ($44.3 million) series D round to ...

BioCentury ISSN 1097-7201